Adma Biologics Inc Revenue Q/Q
What is the Revenue Q/Q of Adma Biologics Inc?
The Revenue Q/Q of Adma Biologics Inc is 78.29%
What is the definition of Revenue Q/Q?
Quarterly revenue growth, year over year, is the increase of a company’s revenue compared to the performance in the corresponding quarter of a previous year expressed as a percentage.
quarterly growth yoy (year over year)
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenue Q/Q of companies in the Health Care sector on NASDAQ compared to Adma Biologics Inc
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Companies with revenue q/q similar to Adma Biologics Inc
- Great Portland Estates Plc has Revenue Q/Q of 78.02%
- Ansal Housing & Construction has Revenue Q/Q of 78.07%
- Dealnet Capital has Revenue Q/Q of 78.07%
- Orient Bell has Revenue Q/Q of 78.16%
- Alfen N.V has Revenue Q/Q of 78.19%
- Catella AB (publ) has Revenue Q/Q of 78.26%
- Adma Biologics Inc has Revenue Q/Q of 78.29%
- Dhunseri Investments has Revenue Q/Q of 78.39%
- Sterling Consolidated has Revenue Q/Q of 78.49%
- Sreeleathers has Revenue Q/Q of 78.52%
- Tantech Ltd has Revenue Q/Q of 78.56%
- Vikas EcoTech has Revenue Q/Q of 78.56%
- Masimo has Revenue Q/Q of 78.68%